US FDA completed inspection of Aurobindo Pharma’s Unit-XII at Bachupally, Telangana, issuing eight procedural observations. The company said there is no financial or operational impact and will respond within timelines.
US FDA completed inspection of Aurobindo Pharma’s Unit-XII at Bachupally, Telangana, issuing eight procedural observations. The company said there is no financial or operational impact and will respond within timelines.